[go: up one dir, main page]

MA37943A1 - 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc - Google Patents

2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc

Info

Publication number
MA37943A1
MA37943A1 MA37943A MA37943A MA37943A1 MA 37943 A1 MA37943 A1 MA 37943A1 MA 37943 A MA37943 A MA 37943A MA 37943 A MA37943 A MA 37943A MA 37943 A1 MA37943 A1 MA 37943A1
Authority
MA
Morocco
Prior art keywords
oxo
snc
indoles
dihydro
disorders
Prior art date
Application number
MA37943A
Other languages
English (en)
Other versions
MA37943B1 (fr
Inventor
Daniela Brunner
Jessica Malberg
Bavani G Shankar
Sabine Kolczewski
Anja Limberg
Eric Prinssen
Claus Riemer
Theodor Stoll
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37943A1 publication Critical patent/MA37943A1/fr
Publication of MA37943B1 publication Critical patent/MA37943B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des 2-oxo-2,3-dihydro-indoles de formule générale (i) dans laquelle (n
MA37943A 2012-09-13 2015-03-20 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc MA37943B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12184249 2012-09-13
PCT/EP2013/068668 WO2014040969A1 (fr) 2012-09-13 2013-09-10 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc

Publications (2)

Publication Number Publication Date
MA37943A1 true MA37943A1 (fr) 2016-04-29
MA37943B1 MA37943B1 (fr) 2016-11-30

Family

ID=47044777

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37943A MA37943B1 (fr) 2012-09-13 2015-03-20 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc

Country Status (22)

Country Link
US (1) US9221816B2 (fr)
EP (1) EP2895476B1 (fr)
JP (1) JP6116693B2 (fr)
KR (1) KR101706877B1 (fr)
CN (1) CN104619701B (fr)
AR (1) AR092555A1 (fr)
AU (1) AU2013314417B2 (fr)
BR (1) BR112015005186A2 (fr)
CA (1) CA2883817C (fr)
CL (1) CL2015000559A1 (fr)
CR (1) CR20150084A (fr)
EA (1) EA027176B1 (fr)
ES (1) ES2590531T3 (fr)
IL (1) IL237266A0 (fr)
MA (1) MA37943B1 (fr)
MX (1) MX2015003330A (fr)
PE (1) PE20150943A1 (fr)
PH (1) PH12015500400A1 (fr)
SG (1) SG11201501923WA (fr)
TW (1) TWI490213B (fr)
WO (1) WO2014040969A1 (fr)
ZA (1) ZA201501262B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130061B2 (ja) * 2013-06-19 2017-05-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体
KR101898364B1 (ko) * 2014-05-22 2018-09-12 에프. 호프만-라 로슈 아게 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
MY186124A (en) * 2014-06-26 2021-06-23 Hoffmann La Roche Indolin-2-one or pyrrolo-pyridin-2-one derivatives
CR20180255A (es) 2015-11-06 2018-06-22 Hoffmann La Roche Derivados de indolin-2-ona
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
EP3371174B1 (fr) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Dérivés d'indolin-2-one
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
CN119866338A (zh) * 2022-06-23 2025-04-22 渤健马萨诸塞州股份有限公司 酪氨酸激酶2抑制剂及其用途
CN116640083A (zh) * 2023-05-30 2023-08-25 江苏海洋大学 一种gpr52调节剂化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417643A1 (de) 1984-05-12 1985-11-14 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
PL147842B1 (en) 1984-05-12 1989-08-31 Method of obtaining novel pyroisobenzimidazoles
DE3445669A1 (de) 1984-12-14 1986-06-19 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4835280A (en) 1985-01-18 1989-05-30 Boehringer Mannheim Gmbh Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
DE3501497A1 (de) 1985-01-18 1986-07-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
DE3803775A1 (de) 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
DE3818830A1 (de) 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
DE3925584A1 (de) * 1989-08-02 1991-02-07 Boehringer Mannheim Gmbh Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP2002522452A (ja) 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
JP2002540096A (ja) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
CN100562513C (zh) * 2003-06-12 2009-11-25 安斯泰来制药有限公司 苯甲酰胺衍生物或其盐
CA2526387A1 (fr) * 2003-06-12 2004-12-23 Astellas Pharma Inc. Derive de benzamide ou sel de ce dernier
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
US20060142247A1 (en) 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
US8106190B2 (en) * 2005-11-30 2012-01-31 Astellas Pharma Inc. 2-aminobenzamide derivatives
KR20100039429A (ko) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
WO2010123139A1 (fr) * 2009-04-24 2010-10-28 持田製薬株式会社 Dérivé arylcarboxamide ayant un groupe sulfamoyle
AU2011326071A1 (en) * 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases

Also Published As

Publication number Publication date
TWI490213B (zh) 2015-07-01
AR092555A1 (es) 2015-04-22
PE20150943A1 (es) 2015-06-20
JP2015529673A (ja) 2015-10-08
MA37943B1 (fr) 2016-11-30
WO2014040969A1 (fr) 2014-03-20
CA2883817A1 (fr) 2014-03-20
KR20150054991A (ko) 2015-05-20
PH12015500400A1 (en) 2015-04-27
EA027176B1 (ru) 2017-06-30
HK1206721A1 (en) 2016-01-15
CR20150084A (es) 2015-04-06
SG11201501923WA (en) 2015-04-29
ES2590531T3 (es) 2016-11-22
CN104619701A (zh) 2015-05-13
US20150284386A1 (en) 2015-10-08
TW201416358A (zh) 2014-05-01
AU2013314417B2 (en) 2016-01-21
US9221816B2 (en) 2015-12-29
BR112015005186A2 (pt) 2017-07-04
JP6116693B2 (ja) 2017-04-19
CL2015000559A1 (es) 2015-07-10
AU2013314417A1 (en) 2015-03-05
CA2883817C (fr) 2017-09-05
IL237266A0 (en) 2015-04-30
EP2895476A1 (fr) 2015-07-22
EA201590438A1 (ru) 2015-06-30
EP2895476B1 (fr) 2016-06-22
ZA201501262B (en) 2016-03-30
KR101706877B1 (ko) 2017-02-15
CN104619701B (zh) 2016-10-19
MX2015003330A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
MA35049B1 (fr) Triazolopyridines
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA35357B1 (fr) Composes de type anilines
EA201591527A1 (ru) Новые производные пиридина
JO3131B1 (ar) مركبات كيميائية
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EA202190619A1 (ru) Противовирусные соединения
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
GEP20166438B (en) Imidazopyrrolidinone compounds
EP2812004A4 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
EP2670439A4 (fr) Principe actif destiné à atténuer des troubles médicaux indésirables
MY170713A (en) Treatment protocol of diabetes type 2
EP2667715A4 (fr) Traitement de troubles du spectre autistique en utilisant l'acide glycyl-l-2-méthylprolyl-l-glutamique
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201491002A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
UA107455C2 (uk) Похідні індолу як протиракові агенти